Lung cancer

Lung cancer is a complex disease, but ongoing research, advanced clinical trials and investigational medicines in the pipeline will continue to uncover answers that save and improve lives.


Lung cancer is one of the most common, and deadly, forms of cancer. Alone, it is responsible for more deaths than breast, colorectal and prostate cancer combined. It remains a significant challenge, both in the clinical and research settings.

And while— a new and innovative treatment option — and existing treatments provide hope for patients, more than two-thirds of all lung cancer patients are diagnosed at a late stage, when the tumours have spread to other parts of the body. Even with surgery, radiation therapy and chemotherapy, lung cancer survival rates are amongst the lowest of all cancer types. Today, however, we have entered an era of new hope. Our understanding of lung cancer keeps growing, giving us a much clearer idea of what takes place in lung cancer cells, how the immune system controls lung cancers and how we can act on this new knowledge.


The key to combating cancer lies in understanding the ways it operates. Like for all cancers, early diagnosis presents the best chances of survival. Unfortunately, lung cancer often remains undiagnosed until it's too late.

For this reason, a critical component of our strategy against lung cancer is exploring how– tissue biopsy, liquid biopsy, immunoassay and imaging technologies – can complement one another and ensure patients are presented with the best solutions at every stage.

Moreover, at the root of our significant advancements is a focus on understanding the genetics and disease pathways behind cancer. Genomic testing and advanced diagnostics can identify mutations in patients to predict the best therapy for the best possible outcomes, ultimately giving physicians and other healthcare professionals the ability to deliver trulyAlthough no single intervention is likely to cure cancer—and there is much work left to do—new possibilities are changing perspectives and prognoses.

More cases of Oncology

View detail of Ontology

© 2024, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.

M-NZ-00000625-v12.0/MR10379/MAY24. This site was last updated JUN2024

ContactDrug SafetyWorldwide LocationslinkedinfacebooktwitterinstagramyoutubePharma solutionsRoche careersRoche cancer treatmentsRoche diagnosticsRoche hubPrivacy statementLegal statementContact UsHealthcare Professionals Portal